Our Team

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.


  • 25 September 2018

    Syndax Announces Changes to its Board of Directors

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of  Jennifer Jarrett  and  William Meury to its Board of Directors, effective today.  Ms. Jarrett and Mr. Meury will succeed  Luke Evnin , Ph.D. and  Henry Chen , who resigned as active members of the Syndax Board of Directors, effective today.

  • 25 September 2018

    Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression.